Compare NBIX & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | LII |
|---|---|---|
| Founded | 1992 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.8B |
| IPO Year | 1996 | 1999 |
| Metric | NBIX | LII |
|---|---|---|
| Price | $130.52 | $521.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 13 |
| Target Price | $180.91 | ★ $566.58 |
| AVG Volume (30 Days) | ★ 1.1M | 449.7K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | ★ 41.95 | 1.11 |
| EPS | ★ 4.67 | 3.35 |
| Revenue | $161,626,000.00 | ★ $5,195,300,000.00 |
| Revenue This Year | $24.73 | $6.85 |
| Revenue Next Year | $13.14 | $5.76 |
| P/E Ratio | ★ $27.99 | $154.27 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $107.96 | $434.06 |
| 52 Week High | $160.18 | $689.44 |
| Indicator | NBIX | LII |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 59.83 |
| Support Level | $124.62 | $479.34 |
| Resistance Level | $135.88 | $529.67 |
| Average True Range (ATR) | 3.58 | 17.73 |
| MACD | -0.12 | 3.38 |
| Stochastic Oscillator | 59.98 | 72.50 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.